Disc Medicine CEO John Quisel Exercises Options and Sells Shares Under Rule 10b5-1 Plan

On June 18, 2026, Disc Medicine, Inc. CEO John D. Quisel executed a series of stock transactions pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. Quisel exercised stock options for 34,000 shares at $9.86 per share, resulting in the acquisition of those shares. Concurrently, he sold 34,000 shares in three separate transactions: 22,927 shares at a weighted average price of $69.9184, 9,522 shares at $70.70, and 1,551 shares at $71.6126. Following these transactions, Quisel's ownership decreased from 260,064 shares to 226,064 common shares, while his remaining stock options decreased from 75,375 to 41,375. The transactions were executed under a pre-established trading plan, which provides legal protection against insider trading allegations by allowing insiders to schedule stock sales in advance based on predetermined criteria.